Personalized Prediction of Lifetime Benefits with Statin Therapy for Asymptomatic Individuals: A Modeling Study

English version České info

Background:
Physicians need to inform asymptomatic individuals about personalized outcomes of statin therapy for primary prevention of cardiovascular disease (CVD). However, current prediction models focus on short-term outcomes and ignore the competing risk of death due to other causes. We aimed to predict the potential lifetime benefits with statin therapy, taking into account competing risks.

Methods and Findings:
A microsimulation model based on 5-y follow-up data from the Rotterdam Study, a population-based cohort of individuals aged 55 y and older living in the Ommoord district of Rotterdam, the Netherlands, was used to estimate lifetime outcomes with and without statin therapy. The model was validated in-sample using 10-y follow-up data. We used baseline variables and model output to construct (1) a web-based calculator for gains in total and CVD-free life expectancy and (2) color charts for comparing these gains to the Systematic Coronary Risk Evaluation (SCORE) charts. In 2,428 participants (mean age 67.7 y, 35.5% men), statin therapy increased total life expectancy by 0.3 y (SD 0.2) and CVD-free life expectancy by 0.7 y (SD 0.4). Age, sex, smoking, blood pressure, hypertension, lipids, diabetes, glucose, body mass index, waist-to-hip ratio, and creatinine were included in the calculator. Gains in total and CVD-free life expectancy increased with blood pressure, unfavorable lipid levels, and body mass index after multivariable adjustment. Gains decreased considerably with advancing age, while SCORE 10-y CVD mortality risk increased with age. Twenty-five percent of participants with a low SCORE risk achieved equal or larger gains in CVD-free life expectancy than the median gain in participants with a high SCORE risk.

Conclusions:
We developed tools to predict personalized increases in total and CVD-free life expectancy with statin therapy. The predicted gains we found are small. If the underlying model is validated in an independent cohort, the tools may be useful in discussing with patients their individual outcomes with statin therapy.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Personalized Prediction of Lifetime Benefits with Statin Therapy for Asymptomatic Individuals: A Modeling Study. PLoS Med 9(12): e32767. doi:10.1371/journal.pmed.1001361
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001361

Souhrn

Zdroje

1. Matheny M, McPheeters ML, Glasser A, Mercaldo N, Weaver RB, et al.. (2011) Systematic review of cardiovascular disease risk assessment tools. Report no. 11-05155-EF-1. Rockville (Maryland): US Agency for Healthcare Research and Quality.

2. FerketBS, ColkesenEB, VisserJJ, SpronkS, KraaijenhagenRA, et al. (2010) Systematic review of guidelines on cardiovascular risk assessment: which recommendations should clinicians follow for a cardiovascular health check? Arch Intern Med 170: 27–40.

3. BrugtsJJ, YetginT, HoeksSE, GottoAM, ShepherdJ, et al. (2009) The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 338: b2376.

4. TaylorF, WardK, MooreTH, BurkeM, Davey SmithG, et al. (2011) Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 1: CD004816.

5. JacksonR, LawesCM, BennettDA, MilneRJ, RodgersA (2005) Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 365: 434–441.

6. Col N (2011) Shared decision making. In: Fischhoff B, Brewer NT, Downs JS, editors. Communicating risks and benefits: an evidence-based user's guide. Silver Spring (Maryland): US Food and Drug Administration.

7. Heart Protection Study Collaborative Group (2011) BulbuliaR, BowmanL, WallendszusK, ParishS, et al. (2011) Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial. Lancet 378: 2013–2020.

8. HalvorsenPA, KristiansenIS (2005) Decisions on drug therapies by numbers needed to treat: a randomized trial. Arch Intern Med 165: 1140–1146.

9. WolbersM, KollerMT, WittemanJC, SteyerbergEW (2009) Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology 20: 555–561.

10. HalvorsenPA, WisloffTF, StovringH, AaslandO, KristiansenIS (2011) Therapeutic decisions by number needed to treat and survival gains: a cross-sectional survey of lipid-lowering drug recommendations. Br J Gen Pract 61: e477–e483.

11. McNeilBJ, PaukerSG, SoxHCJr, TverskyA (1982) On the elicitation of preferences for alternative therapies. N Engl J Med 306: 1259–1262.

12. NijhuisRL, StijnenT, PeetersA, WittemanJC, HofmanA, et al. (2006) Apparent and internal validity of a Monte Carlo-Markov model for cardiovascular disease in a cohort follow-up study. Med Decis Making 26: 134–144.

13. HofmanA, van DuijnCM, FrancoOH, IkramMA, JanssenHL, et al. (2011) The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol 26: 657–686.

14. KollerMT, RaatzH, SteyerbergEW, WolbersM (2011) Competing risks and the clinical community: irrelevance or ignorance? Stat Med 31: 1089–1097.

15. HarrellFEJr, LeeKL, MarkDB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15: 361–387.

16. van DisI, KromhoutD, GeleijnseJM, BoerJM, VerschurenWM (2010) Evaluation of cardiovascular risk predicted by different SCORE equations: the Netherlands as an example. Eur J Cardiovasc Prev Rehabil 17: 244–249.

17. ConroyRM, PyoralaK, FitzgeraldAP, SansS, MenottiA, et al. (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24: 987–1003.

18. GrahamDJ, StaffaJA, ShatinD, AndradeSE, SchechSD, et al. (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292: 2585–2590.

19. BaigentC, KeechA, KearneyPM, BlackwellL, BuckG, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278.

20. GlynnRJ, KoenigW, NordestgaardBG, ShepherdJ, RidkerPM (2010) Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 152: 488–496, W174.

21. DorresteijnJA, VisserenFL, RidkerPM, WassinkAM, PaynterNP, et al. (2011) Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ 343: d5888.

22. ClinRisk (2012) QIntervention [calculator]. Available: http://qintervention.org/index.php. Accessed 20 February 2012.

23. JacksonR (2000) Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ 320: 709–710.

24. HealthDecision (2011) HealthDecision [calculator]. Available: https://www.healthdecision.org/index/tool#. Accessed 20 February 2012.

25. The University of Edinburgh (2010) Cardiovascular risk calculator [calculator]. Available: http://cvrisk.mvm.ed.ac.uk/calculator/calc.asp. Accessed 20 February 2012.

26. GroverSA, LowensteynI, JosephL, KaouacheM, MarchandS, et al. (2007) Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial. Arch Intern Med 167: 2296–2303.

27. WeatherleyND, JacksonPR (2011) The new Sheffield risk and benefit tables for the elderly. QJM 104: 3–12.

28. GroverSA, AbrahamowiczM, JosephL, BrewerC, CoupalL, et al. (1992) The benefits of treating hyperlipidemia to prevent coronary heart disease. Estimating changes in life expectancy and morbidity. JAMA 267: 816–822.

29. WrightJC, WeinsteinMC (1998) Gains in life expectancy from medical interventions—standardizing data on outcomes. N Engl J Med 339: 380–386.

30. PencinaMJ, D'AgostinoRBSr, LarsonMG, MassaroJM, VasanRS (2009) Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation 119: 3078–3084.

31. HuninkMG, GoldmanL, TostesonAN, MittlemanMA, GoldmanPA, et al. (1997) The recent decline in mortality from coronary heart disease, 1980–1990. The effect of secular trends in risk factors and treatment. JAMA 277: 535–542.

32. UnalB, CritchleyJA, CapewellS (2005) Modelling the decline in coronary heart disease deaths in England and Wales, 1981–2000: comparing contributions from primary prevention and secondary prevention. BMJ 331: 614.

33. Hippisley-CoxJ, CouplandC, RobsonJ, BrindleP (2010) Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ 341: c6624.

34. Prospective Studies Collaboration (2007) LewingtonS, WhitlockG, ClarkeR, SherlikerP, et al. (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370: 1829–1839.

35. Cholesterol Treatment Trialists' (CTT) Collaborators (2012) MihaylovaB, EmbersonJ, BlackwellL, KeechA, et al. (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380: 581–590 doi:10.1016/S0140-6736(12)60367-5.

36. ErkelensDW (1991) [Revision of consensus cholesterol.]. Ned Tijdschr Geneeskd 135: 2337–2340.

37. Elias-SmaleSE, ProencaRV, KollerMT, KavousiM, van RooijFJ, et al. (2010) Coronary calcium score improves classification of coronary heart disease risk in the elderly: the Rotterdam study. J Am Coll Cardiol 56: 1407–1414.

38. WieberdinkRG, IkramMK, KoudstaalPJ, HofmanA, VingerlingJR, et al. (2010) Retinal vascular calibers and the risk of intracerebral hemorrhage and cerebral infarction: the Rotterdam Study. Stroke 41: 2757–2761.

39. LevantesiG, ScaranoM, MarfisiR, BorrelliG, RutjesAW, et al. (2007) Meta-analysis of effect of statin treatment on risk of sudden death. Am J Cardiol 100: 1644–1650.

40. Organisation for Economic Co-operation and Development (2011) OECD.StatExtracts: health status [database]. Available: http://stats.oecd.org/index.aspx?DataSetCode=HEALTH_STAT. Accessed 20 February 2012.

41. PletcherMJ, LazarL, Bibbins-DomingoK, MoranA, RodondiN, et al. (2009) Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med 150: 243–254.

42. LazarLD, PletcherMJ, CoxsonPG, Bibbins-DomingoK, GoldmanL (2011) Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation 124: 146–153.

43. WilsonPW, D'AgostinoRB, LevyD, BelangerAM, SilbershatzH, et al. (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837–1847.

44. D'AgostinoRBSr, VasanRS, PencinaMJ, WolfPA, CobainM, et al. (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117: 743–753.

45. O'ConnorAM, BennettCL, StaceyD, BarryM, ColNF, et al. (2009) Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 8: CD001431.